^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
ROZLYTREK is a kinase inhibitor indicated for the treatment of...Adult and pediatric patients 12 years of age and older with solid tumors that...are metastatic or where surgical resection is likely to result in severe morbidity, and...have progressed following treatment or have no satisfactory alternative therapy.
